NATCO Pharma Limited (BOM:524816)
India · Delayed Price · Currency is INR 1,016.75
-158.85 (-13.51%)
At close: May 29, 2026
NATCO Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 40,783 | 44,295 | 39,988 | 27,071 | 19,448 |
Other Revenue | 2,976 | 24 | 32 | 14 | 14 |
| 43,759 | 44,319 | 40,020 | 27,085 | 19,462 | |
Revenue Growth (YoY) | -1.26% | 10.74% | 47.76% | 39.17% | -5.34% |
Cost of Revenue | 970 | 7,274 | 7,487 | 6,544 | 5,845 |
Gross Profit | 42,789 | 37,045 | 32,533 | 20,541 | 13,617 |
Selling, General & Admin | 12,807 | 5,991 | 5,309 | 4,625 | 4,806 |
Other Operating Expenses | 12,641 | 9,029 | 9,599 | 6,072 | 5,952 |
Operating Expenses | 27,514 | 17,383 | 16,827 | 12,443 | 12,383 |
Operating Income | 15,275 | 19,662 | 15,706 | 8,098 | 1,234 |
Interest Expense | -367 | -170 | -120 | -148 | -132 |
Interest & Investment Income | - | 1,905 | 1,013 | 513 | 392 |
Earnings From Equity Investments | 466 | - | - | - | - |
Currency Exchange Gain (Loss) | - | 198 | 103 | 214 | 103 |
Other Non Operating Income (Expenses) | - | 271 | 14 | 130 | -3 |
EBT Excluding Unusual Items | 15,374 | 21,866 | 16,716 | 8,807 | 1,594 |
Merger & Restructuring Charges | - | - | - | -291 | -11 |
Gain (Loss) on Sale of Investments | - | 14 | -7 | -52 | 12 |
Gain (Loss) on Sale of Assets | - | 901 | -17 | 178 | 427 |
Asset Writedown | - | -30 | - | -23 | - |
Pretax Income | 15,374 | 22,914 | 16,735 | 8,619 | 2,022 |
Income Tax Expense | 1,189 | 4,080 | 2,852 | 1,466 | 322 |
Earnings From Continuing Operations | 14,185 | 18,834 | 13,883 | 7,153 | 1,700 |
Net Income to Company | 14,185 | 18,834 | 13,883 | 7,153 | 1,700 |
Minority Interest in Earnings | - | 20 | - | - | - |
Net Income | 14,185 | 18,854 | 13,883 | 7,153 | 1,700 |
Net Income to Common | 14,185 | 18,854 | 13,883 | 7,153 | 1,700 |
Net Income Growth | -24.76% | 35.81% | 94.09% | 320.76% | -61.44% |
Shares Outstanding (Basic) | 179 | 179 | 179 | 183 | 182 |
Shares Outstanding (Diluted) | 179 | 179 | 179 | 183 | 182 |
Shares Change (YoY) | -0.00% | -0.21% | -1.67% | 0.08% | -0.04% |
EPS (Basic) | 79.20 | 105.26 | 77.34 | 39.18 | 9.32 |
EPS (Diluted) | 79.20 | 105.26 | 77.34 | 39.18 | 9.32 |
EPS Growth | -24.76% | 36.10% | 97.40% | 320.39% | -61.42% |
Free Cash Flow | 13,800 | 12,957 | 8,722 | 7,028 | -1,863 |
Free Cash Flow Per Share | 77.05 | 72.34 | 48.59 | 38.50 | -10.21 |
Dividend Per Share | - | 6.000 | 9.500 | 5.500 | 4.500 |
Dividend Growth | - | -36.84% | 72.73% | 22.22% | -14.29% |
Gross Margin | 97.78% | 83.59% | 81.29% | 75.84% | 69.97% |
Operating Margin | 34.91% | 44.37% | 39.25% | 29.90% | 6.34% |
Profit Margin | 32.42% | 42.54% | 34.69% | 26.41% | 8.73% |
Free Cash Flow Margin | 31.54% | 29.24% | 21.79% | 25.95% | -9.57% |
EBITDA | 17,341 | 21,442 | 17,506 | 9,669 | 2,600 |
EBITDA Margin | 39.63% | 48.38% | 43.74% | 35.70% | 13.36% |
D&A For EBITDA | 2,066 | 1,780 | 1,800 | 1,571 | 1,366 |
EBIT | 15,275 | 19,662 | 15,706 | 8,098 | 1,234 |
EBIT Margin | 34.91% | 44.37% | 39.25% | 29.90% | 6.34% |
Effective Tax Rate | 7.73% | 17.81% | 17.04% | 17.01% | 15.93% |
Revenue as Reported | 43,759 | 47,840 | 41,269 | 28,117 | 20,438 |
Advertising Expenses | - | - | - | - | 326 |